











0

## **Outline**

- Transmission of TB on airline flights
- WHO TB and Air Travel Guidelines
- The Canadian experience
- Challenges, partnerships and collaboration

# **TB Transmission on Airlines - 101**


- Potential but low risk flights of 8 hours or longer
- Agent aerosolized *M. tuberculosis*
- Host passengers (and crew?)
- Environment aircraft cabin

PUBLIC HEALTH AGENCY of CANADA | AGENCE DE LA SANTÉ PUBLIQUE du CANADA

10

# **Agent**

- Aerosolized TB bacteria from infectious case
  - Smear and culture status
  - Treatment status
  - Cavitary lesions on x-ray
  - Symptoms
  - Site of disease
  - Documented transmission



Agent — WHO Guidelines

Infectious

Potentially infectious

Non-infectious

MDR/XDR need two negative cultures

Hosts

• Proximity to the index case

- Passengers near by

- Crew (no longer contacts)


• Five rows (usually)

- Case's row

- Two rows ahead of case

- Two rows behind case

• (Susceptibility)







### **Canadian Guidelines**

- Follow-up regardless of time from flight to notification
- Follow-up regardless of flight duration if MDR or laryngeal TB
- Definition of non-infectious

PUBLIC HEALTH AGENCY of CANADA | AGENCE DE LA SANTÉ PUBLIQUE du CANADA

18

# **Investigation Process**

- Diagnosis, travel history
- Reporting form
- · Review and risk assessment

Public Agend	Health y of Canada	Agence de la publique du C	santé anada		contr Reto	ol program. Imer le formulaire	to your provincialiter itorial TB difment rempil à votre program al de lutte antitaberculeuse.		
	Rep	orting Form t	for a Case of Int	ectious Tubero	ulosis (	on an Aircraft	avion		Flight info
1. FLIGHT INFORMATION / RENSEIGNEMENTS SUR LE VOL							•	Flight info	
Date of Flight / Barline / Date du vol Ugne adrienne		Flight No / N* de vol	Origin / Origina	rigine Destination		Flight duration* / Durks du voi*	Activity during flight*" / Activité pendant le vol**		
1.						hs			
2.						hts hts		-	
4.						hs			Case information
			/ "La durée indistries visited inserve etc.				silion, a visità d'autres		Case illioilliation
passagers, a visità	le salon, etc.					Community in so	range, a voice o scarco		
2. CASE INFO	2. CASE INFORMATION / RENSEIGNEMENTS SUR LE CAS LESTATE: FISTATE: Sex							-	
Nom de famille:	Prénom	Seou :							
Data of birth: (************************************									
Country of permanent residence: Citizenship			p/immigration status: de citovenneti/statut d'immigration :				•	Infectiousness	
3. MEDICAL A		MEGRAVATO							Tillectiousiless
Data of symptom on	set (YYYYMMCC)		JH THEN DE ISH	Date of diagnos	ls: (mma	UM/GC)			
Data d'apparition des symptimes : (MAMAMALI)  Smear results: Data: (YYYYAMACO)				Date du diagnostic : (MANAMANICI)  X-rayresults: Date: (MANAMANICI)			Date: PYYYAMATO	-	
Résultats des froitis		D	ato: (NANANINICI)	Résultats des ra	diographie	s:	Data: (AAAA/MACL)		
Direct molecular detection result: Date: (YYYVALMCD) Résellat de la détection Date : (AMMANIACO) molèculaire directe :								•	Drug Sensitivities
Calture result Date: (************************************			Caultius? Yus / Oul No / Non Unicrown / Na sals pas			Unknown / Na sals pas		Drug Schsitivities	
Sensitivity results / F				Laryngeal TB7		□ Yes			
	Susceptible / Sensible	Pending/ En attente	Tubercalose laryngile? Nee / Nee / Nee / Nee Salis pas  Duration and type of treatment before and/or during travel:						
NH		Riksistant		Euros et type de traffement suivi avant et/ou pendant le voyage :			andant le voyage :		
EMB EMB	8	8	8	L				-	EU L. B. I
PZA				Other evidence of transmission?  Autres signes de transmission?				•	Flight Risk
Cough during flight? Toux pendant is vol?		□ Yes / Out □ Non / Non	☐ Ne sais pas	Mask used durk Utilisation d'un pendant le voi?		□ Yes			
Are federal officials ( comme des contacts	such as CBSA, CIC	, RCMP) consider		se? Est-ce que les			BRC) sont considérés		
is case considered a	future flight risk w		o? / Est-ce que le cas				wil?		
☐ Yes / Cei ☐ F			EGNEMENTS EGNEMENTS	elin i a refe		ON			
Form completed by:		Fr	tone:	SUR LA DEC	-ARIA	Province/Territors			
Formulaire rempli pa		Tā	Hiphone:	That cost to war	W	Province ou tenti	oire :		
Data completed: (YYYYATAYCC) Rompil to : (AAAAAAACA				Date sent to TBPC: (YYYYAMATO) Date of errori & LATB : (MANAGOVE)					

**Investigation Process** 

PUBLIC HEALTH AGENCY of CANADA | AGENCE DE LA SANTÉ PUBLIQUE du CANADA

- Notification
  - Quarantine (PHAC), airline
  - International partners determine roles
- Obtain necessary contact information
  - Manifest, PNRs, frequent flyer info, customs declaration cards, passports
- Notifications of jurisdictions regarding passenger contacts
- Obtain results of contact assessments if available

21

# **Canadian Experience**

- Summary of files 2006 to 2007
- 53 cases of TB
  - Male, foreign-born, median 45 years old
  - Most moderately to highly infectious
     (≥ AFB 3+ and cavitary)
- Three drug-resistant (two MDR)
- · Number of notifications increasing


PUBLIC HEALTH AGENCY of CANADA | AGENCE DE LA SANTÉ PUBLIQUE du CANADA

22

## Challenges









#### Other issues


- Preventing travel by infectious persons
  - Prevent travel before it happens!
  - If case is abroad, ensure assessment and treatment before return travel
- Suspect cases
- · Waiting for culture and drug sensitivities
- Need for rapid communication of information

PUBLIC HEALTH AGENCY of CANADA | AGENCE DE LA SANTÉ PUBLIQUE du CANADA

28

#### **Partners and Collaboration**

- Local, provincial/state public health
- Quarantine Services, PHAC
- Airlines
- Canadian Border Services Agency
- Passport Office Foreign Affairs
- CDC Quarantine Service
- International TB Programs



30

#### **Conclusions**

- Small but potential risk of transmission
- Updated WHO guidelines provide clarification
- Collaboration between partners including local, provincial, federal and international jurisdictions is critical
- Number (and complexity) of investigations to increase

